<DOC>
	<DOCNO>NCT01323608</DOCNO>
	<brief_summary>The purpose pilot study determine effect various dos vitamin D supplementation vitamin D store calcium excretion urine subject Thalassemia Major ( TM ) . Subjects TM routinely place vitamin D supplement frequently osteoporosis ( condition bone tissue thin lose density strength ) low vitamin D store . The amount vitamin D supplementation require raise vitamin D store optimal level know TM , determine study . Finally , recent study TM link blood vitamin D level urine calcium excretion , risk factor kidney stone . Therefore , want determine change calcium excretion various vitamin D dose increase vitamin D store . We plan test 3 dos vitamin D 3 month child adult TM . Changes vitamin D blood level urinary calcium determine . The result pilot study use future study examine effect various dos vitamin D supplementation treatment osteoporosis TM .</brief_summary>
	<brief_title>The Effect Vitamin D Supplementation Calcium Excretion Thalassemia : Dose Response Study</brief_title>
	<detailed_description>Specific Aim : To determine effect various dos vitamin D supplementation serum concentration 25 hydroxy vitamin D ( 25OHD ) urinary calcium excretion adult child TM . Hypothesis : Vitamin D supplementation dose result serum 25OHD level &gt; 30 ng/ml result high rate hypercalciuria ( i.e . increase urinary calcium excretion ) child adult TM . The pilot study perform Weill Cornell Medical College , Payson 695 . - Children adult TM , divide 4 group : `` standard '' vitamin D dose ( equivalent 400 IU/day ) , `` intermediate '' vitamin D dose ( equivalent 1000 IU/day ) , `` high '' vitamin D dose ( equivalent 2,000 IU/day ) `` placebo '' group receive inactive ingredient . 10 subject assign group . The duration study 3 month . - While study find difference vitamin D2 D3 , others suggest vitamin D3 may advantageous restore 25 OHD concentration . For reason , vitamin D3 use protocol . - Study schedule study intervention frequency set ( see table ) . All 4 group adhere schedule . After obtain consent , subject `` Baseline Visit '' , include : 1 ) complete physical examination ; 2 ) laboratory evaluation include measurement 25OHD , major circulate form vitamin D reflect body 's vitamin D store . Additional blood urine sample obtain measurement urinary calcium excretion serum Calcium parathyroid hormone ( PTH ) ; 3 ) Dietary calcium intake questionnaire . 4 ) Start study medication . - Subjects return every 2-4 week routine blood transfusion require management Thalassemia . To ensure compliance , study medication administer study personnel routine visit . Vitamin D supply package accord one week worth requirement , i.e . 1,000 IU/day x 7days=7,000 IU `` intermediate '' vitamin D group . The dose administer visit depend interval transfusion , i.e . 7,000 IU x 2weeks , subject `` intermediate '' dose transfuse every two week . - At end 3 month treatment , subject final visit , also schedule coincide routine transfusion visit . Subjects evaluation procedure `` Baseline Visit '' : 1 ) complete physical examination ; 2 ) fast laboratory evaluation include measurement 25OHD , urinary calcium excretion serum Calcium PTH ; 3 ) Dietary calcium intake questionnaire . - Subjects ask take calcium supplementation dose 500 mg daily 6-8 year old 1,000 mg daily 9-18 year old subject . This intervention ensure adequate calcium intake group . All lab process CTSC Core Lab . Study med distribute central pharmacy . Investigational drug administer study personnel transfusion visit ensure compliance . Eligible subject assign study group follow block type enrollment . To ensure equal , near equal sex age distribution , study group match accord sex age . Half subject group compose pediatric subject half compose adult subject . Study Schedule Procedures : - Baseline visit : Physical Exam , 25OHD , Intact PTH &amp; Serum Calcium , 24 hr &amp; spot urine collection Ca/Crea , Calcium intake questionnaire , Vitamin D Supplementation/Placebo . - Every 2-4 week : Administration Vitamin D/Placebo - 3 Month Visit : Physical Exam , 25OHD , Intact PTH &amp; Serum Calcium , 24 hr &amp; spot urine collection Ca/Crea , Calcium intake questionnaire , Vitamin D Supplementation/ Placebo . Primary study endpoint : Changes 25OHD concentration calcium excretion various vitamin D3 dose determined end study constitute primary endpoint .</detailed_description>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<criteria>Thalassemia Major ( TM ) 25 OHD : 1529 ng/ml Age 6 60 year Albumin correct serum Calcium : Normal ( 8.510.5 mg/dl ) Other thalassemia syndrome 25 OHD concentration &lt; 15 ng/ml â‰¥30 ng/ml Subjects young 6 year Hypoparathyroidism Abnormal albumin correct serum Ca ( i.e . total calcium &lt; 8.5 &gt; 10.5 mg/dl ) Medications may adversely affect vitamin D metabolism ( anticonvulsant ) absorption End stage renal , heart , liver disease History Nephrolithiasis Nephrocalcinosis Diseases associate hypercalciuria ( ie . Sarcoidosis , Cushing syndrome , Wilson disease name )</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Thalassemia</keyword>
	<keyword>hypercalciuria</keyword>
	<keyword>vitamin D</keyword>
	<keyword>To conduct pilot study determine effect various dos</keyword>
	<keyword>vitamin D supplementation vitamin D store association calcium excretion</keyword>
</DOC>